Skincare Product Resulted from Fundamental Parthenogenic Stem Cell Research International Stem Cell Corporation (OTCBB:ISCO) (www.intlstemcell.com), has received excellent preliminary results for a new retail skin rejuvenation product that has been developed as a result of its fundamental research into Parthenogenic Stem Cells. Scientists and clinicians at ISCO have discovered that a proprietary combination of the special growth media for human skin tissue created by the company, coupled with the by-products of the production of Parthenogenic Stem Cells, appears to have a dramatic impact on the restoration and retention of skin moisture. The product may have longer term benefits for skin rejuvenation. This discovery represents yet another example of the dynamic relationship between the laboratory research products produced by ISCO's wholly owned subsidiary, Lifeline Cell Technology and the fundamental science of ISCO's stem cell research. Further testing will be conducted to confirm this preliminary data. If subsequent research supports the promising initial results, the Company plans to launch, either directly or through a strategic partnership, a new line of skin rejuvenation products based on this discovery. Dr. Gregory S. Keller, a noted facial plastic surgeon, commented, "This product shows early signs of being a significant breakthrough in providing an oil free skin moisturizing product that might also provide long term benefits in reducing wrinkles and other visible signs of the natural aging process." ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB): International Stem Cell Corporation is a California biotechnology company focused on developing therapeutic and research products. ISCO's technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will minimize immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true "Stem Cell Bank" and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at: www.internationalstemcell.com. For more news and information on International Stem Cell Corporation please visit www.IRGnews.com/coi/ISCO where you can find the CEO's video, a fact sheet on the company, investor presentations, and more. To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0. FORWARD-LOOKING STATEMENTS: Statements pertaining to anticipated future financial and/or operating results, future growth in research, technology, clinical development and potential joint venture and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements. Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman, CEO
760-940-6383
kaldrich@intlstemcell.com
or
Jeffrey Janus, President
760-940-6383
jjanus@intlstemcell.com
or
The Investor Relations Group
212-825-3210
Investor Relations:
Adam S. Holdsworth
aholdsworth@investorrelationsgroup.com
or
Media Relations:
Laura Colontrelle
lcolontrelle@investorrelationsgroup.com | 
